PerkinElmer and Cerep Announce Expansion of Kinase Assay Offerings
News May 05, 2009
At the 15th Annual Society for Biomolecular Sciences (SBS) Conference, PerkinElmer, Inc. announced the expansion of their kinase assay offering. Close to 200 new kinase assays validated with PerkinElmer’s LANCE® Ultra™ technology will be offered for use through Cerep’s drug candidates selection and qualification services.
The collaboration between the two companies first announced in April 2008 delivers custom drug discovery services, through a combination of PerkinElmer’s leading assay technologies, and Cerep’s target screening and drug discovery offerings. Key therapeutic research pathways supported by the new 189 kinase assays include cancer, cardiac disease, central nervous system disorders, inflammation, diabetes, and metabolic disorders, amongst others.
“The extensive range of high quality kinase assays now available for screening and profiling through this collaboration is a compelling complement to the profiling services offered by Cerep. It provides our customers with the expansive range of products and expertise necessary for broad compound screening campaigns to aid their research,” said Richard M. Eglen, PhD, president, Bio-discovery, PerkinElmer.
“Our clients can now benefit from testing their compounds against a broad range of kinase targets via a single platform, validated for performance with PerkinElmer’s innovative LANCE Ultra portfolio and diversified Ulight™ substrates, for consistently high quality results.”
The collaboration with Cerep provides PerkinElmer customers with an option to work with a single vendor throughout the entire drug discovery process. Cerep customers in turn have access to several key assay development and detection platforms from PerkinElmer’s Bio-discovery business, including AlphaScreen®, AlphaLISA®, LANCE®, LANCE® Ultra™ and radioligand binding assays for G protein-coupled receptor (GPCR) and kinase assay development.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.